NEW YORK (GenomeWeb News) — Shares in Sequenom were up 9.51 percent, or $.45, at $5.18, in mid-afternoon trading today after the company said it will work with Qiagen to develop a preanalytical product to enrich nucleic acids for prenatal diagnostics.
As GenomeWeb News reported this morning, Sequenom will retain commercial rights to any tests the companies develop under the partnership.
Qiagen said the goal for the partnership is to develop reliable reagents for the enrichment of small nucleic acid fragments, such as those found in maternal plasma, to analyze cancer and other disorders.